Global
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
Log in
  • Logo
  • Products
  • About us
  • News
  • Contact
  • Sustainability
  • For distributors
  • Aidian Connect
  • Antimicrobial resistance
Search
Logo
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • COVID-19
  • Products available in the USA
Point of care
  • QuikRead go
  • QuikRead 101
  • Aidian LF
  • SD BIOSENSOR STANDARD™ F
  • Pulsar
  • Biosynex
  • GenSure
Read more
QuikRead go
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go accessories
QuikRead go
Microbiology
  • Uricult
  • Uricult Vet
  • Cultura M
Read more
Molecular diagnostics
  • SIBA
Read more
SIBA® licensing and partnering opportunities
Read more
Hygiene monitoring
  • Easicult
  • Hygicult
  • Clean Card PRO
Read more
NEW! A comprehensive guide to monitoring surface hygiene now published
Read more
RIA / Collagens
  • UniQ
Read more
COVID-19
  • Aidian LF SARS-CoV-2 Ag Test
  • Biosynex COVID-19 Ag BSS Rapid Test
  • Pulsar Ecotest COVID-19 Antigen Saliva Test
  • Ecotest COVID-19 Antigen Pen Self-Test Nasal
  • SD BIOSENSOR STANDARD F COVID-19 Tests
  • GenSure COVID-19 Antigen Rapid Test Kit
Read more
Logo
Close
  • Products
    • Point of care
      • QuikRead go
      • QuikRead 101
      • Aidian LF
      • SD BIOSENSOR STANDARD™ F
      • Pulsar
      • Biosynex
      • GenSure
    • Microbiology
      • Uricult
      • Uricult Vet
      • Cultura M
    • Molecular diagnostics
      • SIBA
    • Hygiene monitoring
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / Collagens
      • UniQ
    • COVID-19
      • Aidian LF SARS-CoV-2 Ag Test
      • Biosynex COVID-19 Ag BSS Rapid Test
      • Pulsar Ecotest COVID-19 Antigen Saliva Test
      • Ecotest COVID-19 Antigen Pen Self-Test Nasal
      • SD BIOSENSOR STANDARD F COVID-19 Tests
      • GenSure COVID-19 Antigen Rapid Test Kit
    • Products available in the USA
  • About us
  • News
  • Contact
  • Sustainability
  • For distributors
  • Aidian Connect
  • Antimicrobial resistance
Log in

Popular products

SD BIOSENSOR STANDARD F Analyzer F200 and F2400

SD BIOSENSOR STANDARD F Analyzer F200 and F2400

SD BIOSENSOR STANDARD F Respiratory pathogens

SD BIOSENSOR STANDARD F Respiratory pathogens

SD BIOSENSOR STANDARD F COVID-19 and COVID/FLU A&B pathogens

SD BIOSENSOR STANDARD F COVID-19 and COVID/FLU A&B pathogens

Latest news

View all

QuikRead go® iFOBT is a quantitative feacal test for detecting excess gastrointestinal bleeding

21 March 2023 | News, Product news

Bladder EpiCheck® - A urine marker for monitoring of NMIBC

15 March 2023 | News, Product news

CRP POC testing - a cornerstone in the fight against antimicrobial resistance

14 March 2023 | News, Product news

  • View all
  • No results found
  • Loading...

News

QuikRead go® iFOBT is a quantitative feacal test for detecting excess gastrointestinal bleeding

21 March 2023 | News, Product news

Bladder EpiCheck® - A urine marker for monitoring of NMIBC

15 March 2023 | News, Product news

Homepage Point of care QuikRead go QuikRead go iFOBT

QuikRead go iFOBT

QuikRead go iFOBT is an immunochemical FIT test for detection and quantification of human haemoglobin in faeces in case of suspected bleeding from the lower gastrointestinal tract. The measurement is carried out with the QuikRead go instrument which can be connected to HIS/LIS systems, if needed.

QuikRead go iFOBT kit box
  • Generally
  • Technical data
  • Additionally needed materials
  • Faecal occult blood (FOB) testing and colorectal cancer
  • Documents and materials

Generally

This ready-to-use kit and its straightforward test procedure together with the instrument provide an accurate result in less than three minutes.

The results can be obtained as qualitative or as quantitative, numerical results.

When used as a qualitative test the samples containing human haemoglobin above 15 µg/g faeces (75 ng/ml) are recognized as positives.

The quantitative measurement range starts from 10 µg/g faeces (50 ng/ml) and concentrations up to 200 µg/g faeces (1000 ng/ml) are shown as numerical result. Concentrations above this are displayed as > 200 µg/g (>1000 ng/ml).

QuikRead go iFOBT provides you with

Adaptiveness

  • Quantitative results enable use of national recommendations
  • Results can be weighed against each patient's age and gender or possible risk factors
  • Flexible test procedure is easy to fit into the daily routines of laboratories and in point-of-care
  • Five (5) days sample stability in the sampling vial at 18-25°C allows convenient sampling at home and time to return the sample to the analyzing site

Objectiveness

  • Numerical results in range of 10-200 µg/g (50-1000 ng/ml)
  • Instrument settings allow choosing a qualitative result with a cut-off of 15 µg/g
  • Instrument read results make visual result interpretation unnecessary

Reliability

  • Automated test procedure includes only few manual steps
  • Handy and hygienic sampling vial regulates the quantity of the sample

Proven QuikRead quality

  • No need for manual calibration of the test
  • Results are automatically stored in the instrument’s memory
  • User and patient information can be stored with the results and sent to LIS/HIS when required
  • Connectivity and bi-directional data exchange allow to manage several instruments centrally

Test results should never be used alone, without a complete clinical evaluation.

QuikRead go iFOBT is not registered in the USA.

Technical data

Products available
  • 151051 QuikRead go iFOBT, 50 tests
UseFor in vitro diagnostic use
Method

Immunoturbidimetric

Sample typeFaeces
Instrument information

QuikRead go Instrument

Time to resultLess than 3 minutes
Reading of the resultInstrument read
Storage2 - 8 °C
Shelf life14 months
Transportation2 - 8 °C
Size and weight10 x 14 x 8 cm, 452 g
Full export carton of kits24
Additionally needed

With QuikRead go iFOBT 151051

  • QuikRead go Instrument 133893
  • QuikRead iFOB Sampling Set (50 sampling tubes) 151052
  • QuikRead FOB Positive Control 06027
  • QuikRead go iFOBT Control Quantitative 152390


With QuikRead go iFOBT 136189

  • QuikRead go Instrument 133893
  • QuikRead FOB Sampling Set 138822
  • QuikRead FOB Positive Control 06027
  • QuikRead FOB Control Quantitative 144675
Country of originFinland
RegistrationNot registered in the USA
Registered trademarkQuikRead go is a registered trademark of Aidian Oy

Additionally needed materials

QuikRead iFOB Sampling Set and QuikRead FOB Sampling Set contains 50 sampling tubes with buffer, instructions for use, patient labels and patient instructions. These tubes are designed to collect the defined faeces amount into the buffer and to dispense the correct volume of sample solution into the test cuvette. The sampling tubes are intended for use with QuikRead go iFOBT or QuikRead FOB quantitative tests.

(image)

QuikRead FOB Positive Control is intended for high concentration quality control of QuikRead FOB quantitative and QuikRead go iFOBT assays. If the qualitative measurement is in use, the result should be “Positive” and when the test is used as quantitative, the result should be > 1000 ng/ml or > 200 µg/g

(image)

QuikRead go iFOBT Control Quantitative and QuikRead FOB Control Quantitative kits are intended for low concentration quality control of QuikRead FOB quantitative or QuikRead go iFOBT assays. The control should provide a “Positive” result when the qualitative measurement is used and when the quantitative measurement is used, the result should be within the range indicated on the control vial label.

(image)

Faecal occult blood (FOB) testing and colorectal cancer

Faecal occult blood can be a sign of colorectal cancer

Colorectal cancer (CRC) is a cancer of the colon, rectum, or anus. According to the World Health Organization (WHO), CRC is currently the third most common cancer and the second most common cancer-related cause of death worldwide. Around 1.9 million CRC cases are diagnosed annually.1

Many genetic and environmental factors and clinical conditions increase the risk for CRC. The development of CRC is slow, it usually takes 10-15 years, and it mainly affects individuals older than 50 years old. CRC usually begins with the growth of noncancerous cell clumps, called polyps, in the mucous membrane of the colon. Over time, some of these polyps and adenomas may turn into cancer.

Many people do not experience symptoms in the early stages of CRC. However, the blood vessels of colorectal polyps or cancers are often fragile and easily bleed into the colon or rectum. In healthy individuals, small quantities of lower gastrointestinal bleeding may occur, but it may also be a symptom of a gastrointestinal disorder. In addition to polyps, adenomas, and CRC tumours, other conditions, such as ulcerative colitis and Crohn’s disease, may cause bleeding in the lower intestine. This bleeding is rarely visible by the naked eye in the stool, but the hemoglobin of the faecal occult blood can be detected by the faecal immunochemical test (FIT), such as QuikRead go iFOBT.

Faecal immunochemical test levels correlate with the cancer severity

The faecal hemoglobin concentrations are generally higher in men than women and increase by age2. FIT levels also correlate with the cancer severity3. In symptomatic patients, point of care (POC) QuikRead go iFOBT provides quantitative information on excessive bleeding and aids in triaging patients for further gastrointestinal tract investigations, such as colonoscopy. Negative results assist in the identification of patients who would unlikely benefit from the colonic investigation, or they can be assigned for lower priority. Thus, negative iFOBT results may reduce unnecessary colonoscopies.4 A POC FIT allows immediate test results that can be used for faster decision making and improved risk-stratification of the patients.

Early detection of colorectal cancer improves the chance of survival

The early detection of CRC or its precursors significantly improves the chance for survival, requires less invasive treatment, and reduces treatment costs. Screening of people at moderate risk for CRC have been shown to reduce CRC mortality and incidence.5 Screening of CRC using FIT tests is recommended currently by the Council of Europe in the EU countries and by the American College of Physicians in the USA for individuals between 50-74 years old5,6.

Adjustable cut-off in colorectal screening

The quantitative FIT result enables adjustment of cut-offs according to the patient need or to meet recommendations in the national screening programs in the different countries. The optimal cut-off can be adjusted based on available endoscopic resources, CRC prevalence in the population, and expected participation rate in the screening program7. FIT cut-offs of 20-30 µg/g are recommended when the health care system can organize colonoscopies for approximately 5% of the screened (and FIT positive) patients aged 50-74 years8.


References

  1. World Health Organization. Global Cancer Observatory database. https://gco.iarc.fr/ Accessed 25.2.2022.
  2. McDonald PJ et al. Faecal hemoglobin concentration by gender and age; implications for population – based screening for colorectal cancer. Clin Chem Lab Med. 2012; 50:935-40.
  3. Navarro M et al. Fecal hemoglobin concentration, a good predictor of risk of advanced colorectal neoplasia in symptomatic and asymptomatic Patients. Front Med (Lausanne) 2019; 6:31.
  4. Mclean W et al. Diagnostic accuracy of point of care faecal immunochemical testing using a portable high-speed quantitative analyser for diagnosis in 2-week wait patients. Colorectal Disease 2021; 00:1–11.
  5. European commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis – First Edition. Segnan N, Patrick J, von Karsa L (eds.), 2010, Luxenbourg.
  6. Rex D et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017; 112:1016-1030.
  7. Grazzini G et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 100:259-265.
  8. Hamza S et al. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer. Eur J Cancer 2013; 49:2727-2733.

Documents and materials

Marketing and sales materials

QuikRead go iFOBT Sales Sheet (EN)

QuikRead go iFOBT Brief Instruction (EN)

QuikRead go Family Brochure (EN)

QuikRead go Technical Specifications (EN)

Immunochemical Faecal Occult Blood tests (EN)

QuikRead go iFOB Sampling set ePoster Labquality Days 2018 (EN)

QuikRead go Control Information (EN)

QuikRead go workstation Flyer (EN)

Stories

Immunochemical Faecal Occult Blood tests (EN)

Videos

Instructions for use

(For informative use only. Kindly always refer to the latest package insert in the kit.)

QuikRead go iFOBT IFU (GB, DE, FR, EE) 151051

QuikRead go iFOBT IFU (FI, SE, NO, DK) 151051

QuikRead go iFOBT IFU (CZ, SK, ES, NL) 151051

QuikRead iFOB Sampling Set IFU (GB, DE, FR, NL, ES, EE, CZ, PL, SI, SE, NO, FI, DK) 151052

QuikRead iFOB Sampling Set Patient IFU, 151052

QuikRead FOB Positive Control IFU (GB, DE, FR, NL, ES, IT, CZ, SK, HU, PL, SI, SE, NO, DK, FI), 06027

QuikRead go iFOBT Control Quantitative (GB, FR, DE, NL, ES, IT, SK, CZ, EE, SI, PL, SE, DK, NO, FI), 152390

Revision history QuikRead iFOB Sampling Set (GB, DE, FR, ES, NL, EE, CZ, SK, PL, SE, NO, DK, FI), 151052

Safety Data Sheet

If you wish to receive a Safety data sheet, please contact: product.support@aidian.eu

Interested in these products? Please contact

  • Head office
  • Contact in your country

Aidian Oy

Koivu-Mankkaan tie 6 B,
FI-02200 Espoo,
Finland

P.O. Box 83,
FI-02101 Espoo,
Finland

+358 10 309 3000

Invoicing addresses

E-invoice
Basware 003718552161

Invoicing address
Aidian Oy,
P.O. Box 33,
FI-02101 Espoo,
Finland

Business ID FI18552161

  • Contact
    • Contact in your country
    • Product-specific inquiries
    • Sales related inquiries
  • Aidian Connect
  • Aidian Academy
  • Careers
  • Sustainability
  • Privacy
    • Privacy Policy
    • Privacy Statements
    • Cookie Policy
    • Social Media Policy
    • Unsubscribe
  • Products
    • QuikRead go
    • QuikRead
    • Aidian LF
    • Easicult
    • Hygicult
    • Clean Card PRO
    • Uricult
    • Uricult Vet
    • Cultura M
    • UniQ
    • SIBA
    • Pulsar
    • GenSure
    • Biosynex
    • SD BIOSENSOR STANDARD™ F
    • COVID-19 tests
Copyright © 2023 Aidian

This website uses cookies

We use cookies to personalize content and ads, and to analyze our traffic and improve our service.

Manage Preferences

Necessary (Required)

Cookies that the site cannot function properly without. This includes cookies for access to secure areas and CSRF security. Please note that Craft’s default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.
— CraftSessionId
Provider: this site
Expiration: Session
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionId config setting. This cookie will expire as soon as the session expires.
— *_identity
Provider: this site
Expiration: Persistent
Description: When you log into the Control Panel, you will get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
— *_username
Provider: this site
Expiration: Persistent
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
— CRAFT_CSRF_TOKEN
Provider: this site
Expiration: Session
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.

Statistics

Statistic cookies help us understand how visitors interact with websites by collecting and reporting information anonymously.
— _ga
Provider: Google
Expiration: 2 years
Description: Visitor identification
— _gid
Provider: Google
Expiration: 24 hours
Description: User journey
— _gat_UA-*
Provider: Google
Expiration: 10 minutes
Description: Throttling request rate

Marketing

Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
Hide Details